Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®

References

• Luna EJ, Gattas VL. Effectiveness of the Brazilian influenza vaccination policy, a systematic review. Rev Inst Med Trop Sao Paulo. 2010;52:175-81. doi:10.1590/S0036-46652010000400002. PMID:21748222
   PubMed Web of Science ®Google Scholar
• Portal Brasil. Perguntas e respostas sobre vacinação contra a gripe [Website in Portuguese]. [accessed 15 Nov 2016]. http://www.brasil.gov.br/saude/2014/04/perguntas-e-respostas-sobre-vacinacao-contra-a-gripe
   Google Scholar
• Alonso WJ, Viboud C, Simonsen L, Hirano EW, Daufenbach LZ, Miller MA. Seasonality of influenza in Brazil: A traveling wave from the Amazon to the subtropics. Am J Epidemiol. 2007;165:1434-42. doi:10.1093/aje/kwm012. PMID:17369609
   PubMed Web of Science ®Google Scholar
• Alves L. Annual flu vaccination campaign starts in Brazil. Hawthorne, NY: The Rio Times/Brazil News Agency, Inc; 2015 May 4 [accessed 2017 May 9]. http://riotimesonline.com/brazil-news/rio-politics/flu-vaccination-campaign-starts-in-brazil/
   Google Scholar
• Proctor GD. “Vaxigrip” influenza vaccine. Med J Aust. 1984;141:136. PMID:6738435
   PubMed Web of Science ®Google Scholar
• Arnoux S, Weinberger C, Gessner BD. Vaccine-preventable influenza disease burden from clinical trials of Vaxigrip – an inactivated split virion influenza vaccine – supports wider vaccine use. Vaccine. 2007;25:7720-31. doi:10.1016/j.vaccine.2007.08.063. PMID:17920168
   PubMed Web of Science ®Google Scholar
• Delore V, Salamand C, Marsh G, Arnoux S, Pepin S, Saliou P. Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip. Vaccine. 2006;24:1586-92. doi:10.1016/j.vaccine.2005.10.008. PMID:16271424
   PubMed Web of Science ®Google Scholar
• France EK, Glanz JM, Xu S, Davis RL, Black SB, Shinefield HR, Zangwill KM, Marcy SM, Mullooly JP, Jackson LA, et al. Safety of the trivalent inactivated influenza vaccine among children: A population-based study. Arch Pediatr Adolesc Med. 2004;158:1031-6. doi:10.1001/archpedi.158.11.1031. PMID:15520339
   PubMed Web of Science ®Google Scholar
• Hambidge SJ, Glanz JM, France EK, McClure D, Xu S, Yamasaki K, Jackson L, Mullooly JP, Zangwill KM, Marcy SM, et al. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA. 2006;296:1990-7. doi:10.1001/jama.296.16.1990. PMID:17062862
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use. Note for guidance on harmonisation of requirements for influenza vaccines. 1997 March 12 [accessed 2017 May 9]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf
   Google Scholar
• Committee for Medicinal Products for Human Use. Guideline on influenza vaccines. Non-clinical and clinical module. London, UK: European Medicines Agency; 2016 Jul 21 [accessed 2017 May 9]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500211324.pdf
   Google Scholar
• Haq K, McElhaney JE. Immunosenescence: Influenza vaccination and the elderly. Curr Opin Immunol. 2014;29:38-42. doi:10.1016/j.coi.2014.03.008. PMID:24769424
   PubMed Web of Science ®Google Scholar
• Grohskopf LA, Shay DK, Shimabukuro TT, Sokolow LZ, Keitel WA, Bresee JS, Cox NJ. Prevention and control of seasonal influenza with vaccines. Recommendations of the advisory committee on immunization practices–United States, 2013–2014. MMWR Recomm Rep. 2013;62:1-43.
   Web of Science ®Google Scholar
• Houdouin V, Lavis N, Meyzer C, Jeziorski E, Merlin E, Pinquier D, Deschenes G, Mothe E, Petit C, Plantaz D, et al. Safety of the Northern Hemisphere 2014/2015 formulation of the inactivated split-virion intramuscular trivalent influenza vaccine. Vaccine Reports. 2016;6:1-7. doi:10.1016/j.vacrep.2016.07.001
   Google Scholar
• Beyer WE, Palache AM, Kerstens R, Masurel N. Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies. Eur J Clin Microbiol Infect Dis. 1996;15:65-70. doi:10.1007/BF01586187. PMID:8641306
   PubMed Web of Science ®Google Scholar
• Troy JD, Hill HR, Ewell MG, Frey SE. Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE smallpox vaccine. Vaccine. 2015;33:5425-31. doi:10.1016/j.vaccine.2015.08.032. PMID:26319063
   PubMed Web of Science ®Google Scholar
• Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis. 2011;204:1879-85. doi:10.1093/infdis/jir661. PMID:21998477
   PubMed Web of Science ®Google Scholar
• Trombetta CM, Montomoli E. Influenza immunology evaluation and correlates of protection: A focus on vaccines. Expert Rev Vaccines. 2016;15:967-76. doi:10.1586/14760584.2016.1164046. PMID:26954563
   PubMed Web of Science ®Google Scholar
• Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, Tsai T, Clemens R, Rappuoli R. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J. 2011;30:1081-5. doi:10.1097/INF.0b013e3182367662. PMID:21983214
   PubMed Web of Science ®Google Scholar
• Gravenstein S, Drinka P, Duthie EH, Miller BA, Brown CS, Hensley M, Circo R, Langer E, Ershler WB. Efficacy of an influenza hemagglutinin-diphtheria toxoid conjugate vaccine in elderly nursing home subjects during an influenza outbreak. J Am Geriatr Soc. 1994;42:245-51. doi:10.1111/j.1532-5415.1994.tb01746.x. PMID:8120307
   PubMed Web of Science ®Google Scholar
• Pepin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine. 2013;31:5572-8. doi:10.1016/j.vaccine.2013.08.069. PMID:24016810
   PubMed Web of Science ®Google Scholar